Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.

@article{Papoutsaki2007AdalimumabFS,
  title={Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.},
  author={Marina Papoutsaki and Maria-Sole Chimenti and Antonio Costanzo and Marina Talamonti and Arianna Zangrilli and Alessandro Giunta and Luca Bianchi and Sergio Chimenti},
  journal={Journal of the American Academy of Dermatology},
  year={2007},
  volume={57 2},
  pages={269-75}
}
BACKGROUND Psoriasis is a chronic, genetically determined, immune-mediated, inflammatory skin disease affecting approximately 2% to 3% of the Caucasian population. Previously reported data demonstrated adalimumab to be an efficacious treatment of psoriatic arthritis and plaque-type psoriasis. Adalimumab is a fully human monoclonal antibody IgG1 against tumor necrosis factor alpha. OBJECTIVE To evaluate the efficacy and safety of adalimumab, in the treatment of psoriasis patients whose disease… CONTINUE READING